Amneal’s generic Renvela comes to market
Amneal Pharmaceuticals has launched sevelamer carbonate tablets, 800 mg, in 270-count bottles. This generic from the Bridgewater, N.J.-based company is an AB-rated therapeutic equivalent to Renvela.
Amneal also launched five other products in addition to sevelamer carbonate:
"Our approval and launch of sevelamer carbonate tablets is yet another example of Amneal's commitment to successfully provide complex pharmaceutical products to the US market," Jim Luce, Amneal executive vice president of sales and marketing, said. "Our pipeline continues to grow with more than 132 ANDAs filed and another 140 in development."
Amneal also launched five other products in addition to sevelamer carbonate:
- Progesterone capsules, AB-rated equivalent to Prometrium in 100-mg and 200-mg strengths;
- Bumetanide tablets, USP, AB-rated to Bumex, in 0.5 mg, one-mg and two-mg strengths;
- Ezetimibe and Simvastatin tablets, an AB-rated generic for Vytorin in four strengths;
- Clonidine HCl Extended-Release Tablets, AB1-rated to Kapvay in 0.1 mg strength; and
- Triamcinolone Acetonide Injectable Suspension, USP in 40-mg/mL strength.
"Our approval and launch of sevelamer carbonate tablets is yet another example of Amneal's commitment to successfully provide complex pharmaceutical products to the US market," Jim Luce, Amneal executive vice president of sales and marketing, said. "Our pipeline continues to grow with more than 132 ANDAs filed and another 140 in development."